Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of obexelimab in relapsing multiple sclerosis
ISRCTN78327800Phase 2Completed
- Sponsor
- Zenas BioPharma
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of obexelimab in multiple sclerosis (MS), sponsored by Zenas BioPharma. Started Aug 2024; status: completed.
02
Drugs
obexelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN78327800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78327800.